Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Neuropeptides ; 47(2): 93-7, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23375440

ABSTRACT

Oxytocin (OXT), a nonapeptide hormone of posterior pituitary, reaches the central nervous system from systemic blood circulation with a difficulty because of the blood-brain barrier (BBB). The interest has been expressed in the use of the nasal route for delivery of OXT to the brain directly, exploiting the olfactory pathway. Our previous study has demonstrated that OXT in the central nervous system rather than the blood circulation plays an important role in rat pain modulation. The communication tried to investigate the interaction between the OXT and pain modulation in Chinese patients with headache to understand the OXT effect on human pain modulation. The results showed that (1) intranasal OXT could relieve the human headache in a dose-dependent manner; (2) OXT concentration in both plasma and cerebrospinal fluid (CSF) increased significantly in headache patients in relation with the pain level; and (3) there was a positive relationship between plasma and CSF OXT concentration in headache patients. The data suggested that intranasal OXT, which was delivered to the central nervous system through olfactory region, could treat human headache and OXT might be a potential drug of headache relief by intranasal administration.


Subject(s)
Headache/drug therapy , Oxytocin/therapeutic use , Pain/drug therapy , Administration, Intranasal , Adult , Asian People , Dose-Response Relationship, Drug , Female , Headache/physiopathology , Humans , Male , Middle Aged , Oxytocin/blood , Oxytocin/cerebrospinal fluid , Pain/physiopathology , Pain Measurement/drug effects , Young Adult
2.
Peptides ; 38(1): 100-4, 2012 Nov.
Article in English | MEDLINE | ID: mdl-22963731

ABSTRACT

Arginine vasopressin (AVP), a nonapeptide hormone of posterior pituitary, reaches the central nervous system from systemic blood circulation with a difficulty because of the blood-brain barrier (BBB). The interest has been expressed in the use of the nasal route for delivery of AVP to the brain directly, exploiting the olfactory pathway. Our previous study has demonstrated that AVP in the brain rather than the spinal cord and blood circulation plays an important role in rat pain modulation. For understanding the role of AVP on pain modulation in human, the communication tried to investigate the effect of intranasal AVP on human headache. The results showed that (1) AVP concentration in both plasma and cerebrospinal fluid (CSF) increased significantly in headache patients, who related with the headache level; (2) there was a positive relationship between plasma and CSF AVP concentration in headache patients; and (3) intranasal AVP could relieve the human headache in a dose-dependent manner. The data suggested that intranasal AVP, which was delivered to the brain through olfactory region, could treat human headache and AVP might be a potential drug of pain relief by intranasal administration.


Subject(s)
Arginine Vasopressin/administration & dosage , Arginine Vasopressin/therapeutic use , Headache/drug therapy , Administration, Intranasal , Adult , Arginine Vasopressin/blood , Arginine Vasopressin/cerebrospinal fluid , Dose-Response Relationship, Drug , Female , Humans , Male , Middle Aged , Treatment Outcome , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...